Enhancing the Therapeutic Effect in Alzheimer's Disease Drugs

Detalhes bibliográficos
Autor(a) principal: Martins, M. Margarida
Data de Publicação: 2023
Outros Autores: Branco, Paula S., Ferreira, Luísa M.
Tipo de documento: Outros
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10362/158162
Resumo: Publisher Copyright: © 2023 NOVA School of Science and Technology. ChemistrySelect published by Wiley-VCH GmbH.
id RCAP_3226521a6baefde3217657f4d5f4b3d1
oai_identifier_str oai:run.unl.pt:10362/158162
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Enhancing the Therapeutic Effect in Alzheimer's Disease DrugsThe role of Polypharmacology and Cholinesterase inhibitorsAlzheimer's diseaseBiological activityCholinesterase inhibitorsCurrent hypothesesDrug designMulti-target directed ligandsChemistry(all)Publisher Copyright: © 2023 NOVA School of Science and Technology. ChemistrySelect published by Wiley-VCH GmbH.Alzheimer's disease (AD) is a devastating syndrome that accounts for 60–70 % of all dementia cases, putting an enormous burden on global healthcare and economy. Unfortunately, there is no cure for AD, and the currently approved drugs are limited in their effects. Given the various pathological mechanisms behind AD, the “one-target, one-drug” paradigm for drug design became obsolete, and a new paradigm, polypharmacology, emerged. Consequently, a greater focus has been put towards multi-target directed ligands (MTDLs), as these can regulate several targets operating in the disease network. Parallel to that, cholinesterase inhibitors have regained popularity after decades of being considered only symptomatic agents with no disease-modifying properties. In this review, the current AD hypotheses and therapeutic targets, the concept of polypharmacology in AD pathology and the importance of cholinesterases in the pathogenesis and biochemical processes of AD are discussed, with a final overview of the current development in cholinesterase-based MTDLs.DQ - Departamento de QuímicaRUNMartins, M. MargaridaBranco, Paula S.Ferreira, Luísa M.2023-09-22T22:17:09Z2023-03-132023-03-13T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/other16application/pdfhttp://hdl.handle.net/10362/158162eng2365-6549PURE: 72195289https://doi.org/10.1002/slct.202300461info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2024-05-22T18:14:35Zoai:run.unl.pt:10362/158162Portal AgregadorONGhttps://www.rcaap.pt/oai/openairemluisa.alvim@gmail.comopendoar:71602024-05-22T18:14:35Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Enhancing the Therapeutic Effect in Alzheimer's Disease Drugs
The role of Polypharmacology and Cholinesterase inhibitors
title Enhancing the Therapeutic Effect in Alzheimer's Disease Drugs
spellingShingle Enhancing the Therapeutic Effect in Alzheimer's Disease Drugs
Martins, M. Margarida
Alzheimer's disease
Biological activity
Cholinesterase inhibitors
Current hypotheses
Drug design
Multi-target directed ligands
Chemistry(all)
title_short Enhancing the Therapeutic Effect in Alzheimer's Disease Drugs
title_full Enhancing the Therapeutic Effect in Alzheimer's Disease Drugs
title_fullStr Enhancing the Therapeutic Effect in Alzheimer's Disease Drugs
title_full_unstemmed Enhancing the Therapeutic Effect in Alzheimer's Disease Drugs
title_sort Enhancing the Therapeutic Effect in Alzheimer's Disease Drugs
author Martins, M. Margarida
author_facet Martins, M. Margarida
Branco, Paula S.
Ferreira, Luísa M.
author_role author
author2 Branco, Paula S.
Ferreira, Luísa M.
author2_role author
author
dc.contributor.none.fl_str_mv DQ - Departamento de Química
RUN
dc.contributor.author.fl_str_mv Martins, M. Margarida
Branco, Paula S.
Ferreira, Luísa M.
dc.subject.por.fl_str_mv Alzheimer's disease
Biological activity
Cholinesterase inhibitors
Current hypotheses
Drug design
Multi-target directed ligands
Chemistry(all)
topic Alzheimer's disease
Biological activity
Cholinesterase inhibitors
Current hypotheses
Drug design
Multi-target directed ligands
Chemistry(all)
description Publisher Copyright: © 2023 NOVA School of Science and Technology. ChemistrySelect published by Wiley-VCH GmbH.
publishDate 2023
dc.date.none.fl_str_mv 2023-09-22T22:17:09Z
2023-03-13
2023-03-13T00:00:00Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/other
format other
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10362/158162
url http://hdl.handle.net/10362/158162
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 2365-6549
PURE: 72195289
https://doi.org/10.1002/slct.202300461
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv 16
application/pdf
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv mluisa.alvim@gmail.com
_version_ 1817545956971773952

Registros relacionados